Astellas Pharma Inc.
4503.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥2,589,532 | ¥2,942,766 | ¥3,427,096 | ¥3,534,802 |
| - Cash | ¥188,372 | ¥335,687 | ¥376,840 | ¥315,986 |
| + Debt | ¥831,426 | ¥1,005,716 | ¥200,007 | ¥212,744 |
| Enterprise Value | ¥3,232,586 | ¥3,612,795 | ¥3,250,263 | ¥3,431,560 |
| Revenue | ¥1,912,323 | ¥1,603,672 | ¥1,518,619 | ¥1,296,163 |
| % Growth | 19.2% | 5.6% | 17.2% | – |
| Gross Profit | ¥1,426,355 | ¥1,311,187 | ¥1,230,266 | ¥1,043,154 |
| % Margin | 74.6% | 81.8% | 81% | 80.5% |
| EBITDA | ¥248,303 | ¥195,340 | ¥240,459 | ¥241,030 |
| % Margin | 13% | 12.2% | 15.8% | 18.6% |
| Net Income | ¥50,747 | ¥17,045 | ¥98,714 | ¥124,086 |
| % Margin | 2.7% | 1.1% | 6.5% | 9.6% |
| EPS Diluted | 28.24 | 9.47 | 54.09 | 67.05 |
| % Growth | 198.2% | -82.5% | -19.3% | – |
| Operating Cash Flow | ¥201,613 | ¥172,475 | ¥327,767 | ¥257,444 |
| Capital Expenditures | -¥37,003 | -¥82,497 | -¥88,541 | -¥76,448 |
| Free Cash Flow | ¥164,610 | ¥89,978 | ¥239,226 | ¥180,996 |